The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Filing for WHO Emergency Use Authorisation this month
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Advances deployment of mRNA technology across vaccines and therapeutics development
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Subscribe To Our Newsletter & Stay Updated
